188 Data are presented as proportions n with corresponding percentages (%), mean ± standard deviation (SD) or as median [interquartile range, IQR] in case of continuous variables. P-values ≤ 0.05 were considered statistically significant. †Use of TNF-α-antagonists included use of infliximab, adalimumab, golimumab and certolizumab pegol. Abbreviations: BMI, body-mass index; CD, Crohn’s disease; HBI, Harvey-Bradshaw Index; IBD, inflammatory bowel disease; TNF-α, tumor necrosis factor alpha; SCCAI, Simple Clinical Colitis Activity Index; UC, ulcerative colitis. Chapter 6 Active disease (≥5) 119 (36.7) 44 (42.3) 75 (34.1) - SCCAI 257 (88.9) 84 (85.7) 173 (90.6) - 0.14 Remission (≤2) 152 (59.1) 44 (52.4) 108 (62.4) - Active disease (>2) 105 (40.9) 40 (47.6) 65 (37.6) - Surgical history Ileocecal resection, n (%) 132 (20.6) 40 (18.9) 92 (21.5) - 0.47 Colon resection (or partial), n (%) 146 (22.8) 55 (25.9) 91 (21.3) - 0.19 Small intestinal (partial) resection, n (%) 82 (12.8) 29 (13.7) 53 (12.4) - 0.71
RkJQdWJsaXNoZXIy MjY0ODMw